The drug industry is at the center of drug price debates in congress. Government budget pressures in many countries often turn to the health care systems for cuts. The US elections in coming years are a potential source of renewed focus on the high profit levels of branded drug companies versus the human rights to health care at lower prices. On another front insurers are encouraging policy holders to use generic drugs. Overall new drug pipelines are lower as the ability of a drug company to recover R&D expenses is crimped- seen in modestly declines in return on invested capital for the industry.
Historically the drug industry has underperformed during Fed Rate Cuts
Allergan (AGN) Biogen Idec (BIIB) Bristol-Myers Squibb Company (BMY) Celgene (CELG) Genzyme (GENZ) Gilead Sciences (GILD) GlaxoSmithKline (GSK) Eli Lilly and Company (LLY) Merck (MRK) Novartis AG (NVS) Novo Nordisk A/S (NVO) Pfizer (PFE) Sanofi-Aventis SA (SNY) Schering-Plough (SGP) Wyeth (WYE)